<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00549068</url>
  </required_header>
  <id_info>
    <org_study_id>HMR4003B_4031</org_study_id>
    <nct_id>NCT00549068</nct_id>
  </id_info>
  <brief_title>POWER Point of Care Effect on Satisfaction of Treatment</brief_title>
  <official_title>Impact of NTx Point of Care (POC) Device on Patient Satisfication With Actonel 35mg Once a Seek Treatment a Multicenter Prospective Open Label Randomized Controlled Community Practice-based Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Procter and Gamble</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      To compare the subject satisfaction rating in women treated for postmenopausal osteoporosis
      with Actonel 35mg Once-a-Week for 24 weeks, and receiving feedback information, after 12
      weeks of treatment, based on bone resorption marker results using the NTx Point-Of-Care (POC)
      device, to similar women treated as per regular clinical practice
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2003</start_date>
  <completion_date type="Actual">November 2004</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compare subject satisfaction rating in women treated for postmenopausal osteoporosis with Actonel® 35 mg Once-a-Week for 24 weeks, and receiving feedback information after 12 weeks of treatment to similar women monitored as per regular clinical practice</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare subject satisfaction with Actonel® 35 mg Once-a-Week in subject subgroups: previously treated with biphosphonates, HRT, raloxifene, fluoride, or calcitonin within past 2 years vs. those previously non treated</measure>
  </secondary_outcome>
  <enrollment type="Actual">2433</enrollment>
  <condition>Osteoporosis, Postmenopausal</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risedronate Sodium (Actonel)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women diagnosed with postmenopausal osteoporosis using community practice standards

          -  Women previously non-treated for osteoporosis, OR treated for osteoporosis with
             biphosphonates (alendronate, etidronate), hormone replacement therapy estrogen,
             estrogen-related drugs, progesterone, subcutaneous estrogen implant), raloxifene,
             fluoride, or calcitonin within the past 2 years but discontinued prior to enrolment
             into the study either due to:lack of effect or intolerance

        Exclusion Criteria:

          -  Subjects treated with Actonelr 5 mg daily,

          -  Mental condition rendering the subject unable to understand the nature, scope, and
             possible consequences of the study

          -  Subject unlikely to comply with protocol, e.g., uncooperative attitude, inability to
             return for follow-up visits, and unlikelihood of completing the study

          -  Known/Suspected hypersensitivity to any component of Actonelr 35 mg Once-a-Week

          -  Known/Suspected hypocalcaemia

          -  Known/Suspected severe renal impairment (creatinine clearance &lt; 30ml/min)

          -  Known/Suspected hyperparathyroidism

          -  Known/Suspected hyperthyroidism

          -  Known/Suspected active urinary tract infection

          -  Known high urine levels of calcium (3 4mg/ml)

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary Tzortzis</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <verification_date>December 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 24, 2007</study_first_submitted>
  <study_first_submitted_qc>October 24, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 25, 2007</study_first_posted>
  <last_update_submitted>December 4, 2009</last_update_submitted>
  <last_update_submitted_qc>December 4, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 7, 2009</last_update_posted>
  <responsible_party>
    <name_title>Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Osteoporosis, Postmenopausal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Risedronate Sodium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

